Nexstim Plans 10-Year Exclusive Partnership With Sinaptica for Alzheimer's Treatment

• Nexstim is pursuing a worldwide, 10-year exclusive partnership with Sinaptica Therapeutics, subject to definitive agreements being signed before the end of 2026.
• The planned collaboration covers development, manufacturing and supply of a precision neuromodulation system for Alzheimer's disease and mild cognitive impairment.
• Financial terms include an upfront exclusivity signing fee, milestone-based development payments and clinical and commercial system sales.
• Separately, collaboration with Brainlab supports commercialization of its diagnostics business through Brainlab's sales infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.